Data Byte: IPO queue picks up post-election

While IPO activity came to a brief standstill early last month in anticipation of post-election market volatility, at least eight biotechs have since lined up for a NASDAQ listing. 

And the postmarket performance of Olema Pharmaceuticals Inc. (NASDAQ:OLMA), the first biotech to go public on NASDAQ following the U.S. election, indicates that investor appetite remains robust. Olema, a cancer company led by former AstraZeneca plc (LSE:AZN; NYSE:AZN) CMO Sean Bohen, rose $30 (158%) to $49 on its first day of trading on Nov. 19 after raising $209 million in an upsized IPO; it closed Tuesday at $54.50...